Two Lidoderm Class Action Deals Worth $271M Get Final OK
Law360, San Francisco (September 12, 2018, 10:54 PM EDT) -- A California federal judge on Wednesday approved "excellent" settlements ending claims that Teikoku, Endo and Actavis violated antitrust laws by stalling the release of a generic form of the Lidoderm pain patch, finalizing a $104.75 million deal with end payors and a $166 million deal with direct purchasers, including a combined $85.6 million in attorneys' fees.
End payors included employee health and welfare benefit plans, unions or individuals who purchased the drug from third parties. Last month, their attorneys asked for $38.6 million in attorneys' fees, which represents about 37 percent of the total settlement. In June, class counsel for the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!